ERBB2 and breast carcinoma: To our knowledge, this is the first report showing the effects of PIK3CA mutations and PTEN expression on pathological therapeutic effect of neoadjuvant therapy and the prognosis in postmenopausal Asian patients with ER-positive HER2-negative breast cancer.